Rapid RV/LV vs Tempus ECG-AF
AI Verdict
Choose Rapid RV/LV if…
Choose Rapid RV/LV if your clinical setting requires rapid, AI-powered assessment of pulmonary embolism (PE) severity from CTPA scans. This tool is ideal for emergency departments or critical care units needing quick, objective measurements of right and left ventricle ratios to guide immediate patient triage and management decisions for suspected PE.
View Rapid RV/LV →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your practice focuses on proactive risk stratification for atrial fibrillation (AF) in older adult populations. This AI-based algorithm is best suited for cardiology, geriatrics, or internal medicine clinics aiming to identify patients aged 65 or older at increased risk of developing new-onset AF within the next 12 months, enabling earlier intervention and follow-up care.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Rapid RV/LV | Tempus ECG-AF |
|---|---|---|
| Pricing | Contact vendor for pricing information. | Contact vendor |
| Deployment | Unknown | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Rapid RV/LVRapid RV/LV provides direct visual feedback with annotated images and delivers rapid, quantifiable results within minutes of a scan, making it highly intuitive and immediately actionable for clinicians in an acute setting. Tempus ECG-AF, while automating analysis, requires further clinical interpretation of its risk assessment in conjunction with other patient data.
Clinical Value
TieBoth tools are FDA-cleared and offer significant clinical value. Rapid RV/LV provides critical, rapid assessment for an acute, life-threatening condition (PE), directly impacting immediate treatment decisions. Tempus ECG-AF offers valuable predictive insights for proactive management of a chronic condition (AF) to prevent future complications.
Pricing & Value
Tempus ECG-AFTempus ECG-AF explicitly details CMS reimbursement availability with specific CPT codes and a Medicare rate, offering clear financial transparency and a defined pathway for value realization for healthcare providers. Rapid RV/LV's pricing information is only available by contacting the vendor, which lacks transparency.
Enterprise Readiness
Rapid RV/LVRapid RV/LV offers flexible deployment options, including on-premises or hybrid models, and integrates with a broader Rapid platform for triage and notification, suggesting a more comprehensive and adaptable enterprise solution. Both tools are FDA-cleared, HIPAA compliant, and offer BAAs, meeting fundamental enterprise requirements.
Innovation
Tempus ECG-AFTempus ECG-AF demonstrates high innovation by leveraging AI to predict the *future* risk of atrial fibrillation from standard 12-lead ECGs, enabling proactive and preventative care based on widely available data. Rapid RV/LV's innovation lies in automating and speeding up critical measurements for acute diagnosis, but the predictive nature of Tempus ECG-AF for preventative health is a distinct leap.
Support & Docs
Rapid RV/LVRapidAI explicitly offers 24/7/365 customer support via email and phone with multiple international numbers, along with a comprehensive 'Resources' section including guides, videos, and FAQs. Tempus AI also provides support and resources, but RapidAI's clearly stated 24/7/365 global availability for direct contact is a stronger offering.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Rapid RV/LV | Tempus ECG-AF |
|---|---|---|
| Tool Name | Rapid RV/LV | Tempus ECG-AF |
| Company | RapidAI (formerly iSchemaView) | Tempus AI, Inc. |
| Description | FDA-cleared AI tool for rapid assessment of pulmonary embolism severity by automatically measuring right and left ventricle ratios from CTPA scans. | FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. |
| Primary Use Case | Rapid assessment of pulmonary embolism severity via RV/LV ratio from CTPA scans. | Identify patients 65+ at increased risk of developing atrial fibrillation/flutter (AF) within 12 months from 12-lead ECGs. |
| Key Features | AI-powered analysis of CTPA images; Automated measurement of right and left ventricle diameters; Calculation of RV/LV ratio; Annotated images showing ventricular measurements; Rapid results (within minutes of scan); Reduces inter-rater variability; Integration with Rapid PE solution; Triage and notification capabilities (as part of the broader Rapid platform). | AI-based algorithm for 12-lead ECG analysis; Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months; Intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery; Results interpreted in conjunction with other diagnostic information and clinical history; Compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems; Trained on over 1.5 million ECGs from over 500,000 patients. |
| Specialties | Cardiology, Pulmonology, Radiology | Cardiology, Geriatrics, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring Rapid RV/LV and Tempus ECG-AF.